COST-EFFECTIVENESS OF SECOND-LINE NILOTINIB VERSUS DASATINIB FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE (PH plus CML-CP) IN ITALY

被引：0
|
作者：
Maheshwari, V [1 ]
Tran, D. [2 ]
Agostoni, G. [3 ]
Filioussi, K. [3 ]
Viana, R. [4 ]
机构：
[1] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[2] Cornerstone Res Grp Inc, Burlington, ON, Canada
[3] Novartis Farma SpA, Origgio, Italy
[4] Novartis, East Hannover, NJ USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN176
引用
收藏
页码：S470 / S470
页数：1
相关论文
共 50 条
  • [31] A single-arm, open-label, multicenter study of complete molecular response (CMR) in patients with newly diagnosed Philadelphia chromosome-positive (Ph plus ) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib
    Savona, Michael R.
    Flinn, Ian W.
    Goldberg, Stuart
    Robles, Robert Leon
    Rizzieri, David
    Radich, Jerald P.
    Mauro, Michael J.
    Ericson, Solveig
    Yi, Sandy
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Efficacy of Nilotinib in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP)
    Cortes, Jorge
    O'Brien, Susan
    Jones, Dan
    Jabbour, Elias
    Konopleva, Marina
    Ferrajoli, Alessandra
    Kadia, Tapan
    Borthakur, Gautam
    Stigliano, Denise
    Shan, Jenny
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 144 - 145
  • [33] TREATMENT, RESPONSE, AND OUTCOME IN UNSELECTED ELDERLY PATIENTS WITH NEWLY DIAGNOSED, CHRONIC PHASE (CP), PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA
    Gugliotta, G.
    Stagno, F.
    De Vivo, A.
    Spitalieri, A.
    Castagnetti, F.
    Fabbiano, F.
    Capodanno, I.
    Mannina, D.
    Salvucci, M.
    Antolino, A.
    Marasca, R.
    Musso, M.
    Crugnola, M.
    Consoli, U.
    Trabacchi, E.
    Musolino, C.
    Cavazzini, F.
    Longo, G.
    Tosi, P.
    Cardinale, G.
    Rizzo, M.
    Soverini, S.
    Martinelli, G.
    Cavo, M.
    Vigneri, P.
    Rosti, G.
    Di Raimondo, F.
    Baccarani, M.
    HAEMATOLOGICA, 2016, 101 : 739 - 740
  • [34] Nilotinib In the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase
    Garnock-Jones, Karly P.
    DRUGS, 2011, 71 (12) : 1579 - 1590
  • [35] MODELING THE SURVIVAL LOSS IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE (PH plus ) CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) SWITCHED FROM IMATINIB MESYLATE TO A GENERIC COPY
    Botteman, M.
    Magestro, M.
    Alwan, A. F.
    VALUE IN HEALTH, 2012, 15 (07) : A422 - A422
  • [36] Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia
    Yood, Marianne Ulcickas
    Oliveria, Susan A.
    Cziraky, Mark
    Hirji, Ishan
    Hamdan, Muhammad
    Davis, Catherine
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (02) : 213 - 219
  • [37] Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia
    Hijiya, Nobuko
    Maschan, Alexey
    Rizzari, Carmelo
    Shimada, Hiroyuki
    Dufour, Carlo
    Goto, Hiroaki
    Kang, Hyoung Jin
    Guinipero, Terri
    Karakas, Zeynep
    Bautista, Francisco
    Ducassou, Stephane
    Yoo, Keon Hee
    Zwaan, Christian Michel
    Millot, Frederic
    Aimone, Paola
    Allepuz, Alex
    Quenet, Sara
    Hourcade-Potelleret, Florence
    Hertle, Sabine
    Sosothikul, Darintr
    BLOOD, 2019, 134 (23) : 2036 - 2045
  • [38] Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis
    Adel, Ahmad
    Abushanab, Dina
    Hamad, Anas
    Abdulla, Mohammad
    Izham, Mohamed
    Yassin, Mohamed
    CANCER CONTROL, 2021, 28
  • [39] Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
    Muresan, B.
    Mamolo, C.
    Cappelleri, J. C.
    Postma, M. J.
    Heeg, B.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (06) : 929 - 940
  • [40] Characterization of Dasatinib Pharmacokinetics and Exposure-Response In Support of Dose Recommendations in Pediatric Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph plus CML) In Chronic Phase (CP)
    Wang, Xiaoning
    Bello, Akintunde
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S119 - S120
12345